The smallpox treatment market involves drugs and vaccines for treatment of smallpox disease. Smallpox is a highly contagious and fatal disease caused by the variola virus. The symptoms include high fever and body aches followed by development of characteristic skin lesions. Although smallpox was eradicated in 1980, concerns remain regarding its potential re-emergence from laboratory stockpiles or intentional release. The available treatment options include antiviral drugs such as cidofovir, brincidofovir and ST-246 which can help reduce symptoms. Vaccines also play a crucial role in prevention of smallpox outbreaks.
The Global Smallpox Treatment Market Size is estimated to be valued at US$ 79.15 Bn in 2024 and is expected to exhibit a CAGR of 27% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the smallpox treatment market are 42 Degrees Company, ScaldoPack, Heat Food & Drink Ltd, Luxfer Magtech Inc., HeatGen, LLC., LMK Thermosafe, Kemira Inc, Ontech operations Inc., and Com-Pac International. These players are involved in development and production of antiviral drugs and smallpox vaccines.
The rising risk of smallpox outbreaks due to bioterrorism activities is driving the demand for prophylactic vaccinations and treatment options. According to reports, over 105 million people will require vaccination post exposure to curb a large outbreak.
Technological advancements include development of second generation smallpox vaccines with better safety profile and thermostability. Recombinant technology is being utilized to develop novel smallpox vaccines with no risk of disease transmission. ST-246 is a novel antiviral being developed under the oversight of US government agencies for treatment of smallpox.
Market Trends
Increasing government investments - Governments worldwide are allocating higher budgets for strengthening preparedness against smallpox bioattacks. This includes funding for vaccine stockpiling, novel drugs development and research.
Focus on domesitc production - With geopolitical risks, many countries are enhancing indigenous production capabilities of critical drugs and vaccines required in case of a smallpox outbreak.
Market Opportunities
Development of ready-to-use thermostable vaccines - There is scope for advanced vaccines that do not require cold chain transportation and storage. This can facilitate stockpiling and distribution in remote areas.
Expanding indications - Companies are exploring efficacy of existing antiviral drugs and vaccines against other dangerous orthopoxviruses such as monkeypox and cowpox. This can boost the revenue stream.
Impact of COVID-19 on Smallpox Treatment Market growth
The COVID-19 pandemic has negatively impacted the growth of the smallpox treatment market. During the initial phase of the pandemic, there was a decline in production and supply chain disruptions led to shortage of essential smallpox drugs. Patients also avoided hospitals and delayed treatment due to fear of virus exposure. However, post pandemic, the market is expected to grow steadily. With rising threats of bioterrorism and possibility of smallpox outbreak in future, governments across the globe are increasing funding for development of new smallpox vaccines and drugs. Manufacturers are also ramping up production levels to meet growing demand. The adoption of digital healthcare solutions further helped continuity of smallpox treatment to some extent.
Geographical regions with highest Smallpox Treatment Market value
North America dominates the smallpox treatment market in terms of value, accounting for over 35% share. The region is home to many leading biotech and pharmaceutical companies involved in research and development of advanced smallpox therapeutics. Favorable regulatory environment and higher healthcare spending have supported market growth. North America is followed by Europe with around 30% share. Countries like Germany, UK and France have major manufacturing facilities that produce essential smallpox vaccines for domestic as well as global markets. Asia Pacific is projected to be the fastest growing region during the forecast period due to increasing healthcare investments, growing biotech industry and rising awareness about smallpox prevention in densely populated countries.
Regions witnessing fastest growth in Smallpox Treatment Market
Asia Pacific region is poised to witness fastest growth in the smallpox treatment market driven by expanding healthcare infrastructure, rapid economic development and large patient pool. China and India represent huge potential, being the most populated countries globally. Rising per capita income has boosted access to advanced smallpox care in Asia Pacific. Initiatives by government and private organizations to strengthen biodefense have propelled regional demand. Additionally, manufacturers are shifting focus towards this region owing to low-cost manufacturing advantages. These factors are expected to fuel Asia Pacific market for smallpox treatment at a significant pace. North America and Europe will maintain their leading positions but Asia Pacific is likely to emerge as the torchbearer of future growth in the coming years.
Get More Insights on Smallpox Treatment Market
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
